Technology | CT Angiography (CTA) | June 16, 2017

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Visipaque is the first FDA-approved contrast agent indicated for non-invasive CCTA procedure 

GE Healthcares imaging agent Visipaque, iodixanol, is now cleared for use with cardiac CT angiography, CCTA

June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s imaging agent Visipaque (iodixanol) Injection. Visipaque 320 mg iodine/mL is an iso-osmolar agent that is now approved for use in coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of adult and pediatric patients 12 years of age or older with suspected coronary artery disease in the United States.

The new CCTA indication allows healthcare practitioners to image the coronary arteries of patients with suspected coronary artery disease (CAD), offering a non-invasive approach to diagnosis. Traditionally, radiologists and cardiologists have utilized invasive coronary angiography (ICA) procedures to diagnose potential CAD in patients, which can be costly and result in longer patient hospital stays. With Visipaque’s CCTA label extension, healthcare practitioners now have an FDA-approved contrast agent in CCTA procedures that can be performed as an outpatient procedure when evaluating patients with suspected CAD.
 
“Coronary heart disease is a major cause of death in the United States,” said Matt Budoff, M.D., FACC, director of cardiac CT and professor of medicine, Harbor-UCLA Medical Center, Torrance, Calif. “We are excited about the label extension of Visipaque as the first FDA approved iodinated contrast media for use in CCTA. Having an approved contrast agent for CCTA may facilitate the use of CCTA as a gatekeeper to ICA in patients with mild to moderate coronary artery disease, sparing patients from a more invasive procedure and long recovery times.”

Label extension approval for Visipaque 320 mg Iodine/mL for CCTA was evaluated in two prospective, multicenter clinical studies in a total of 1,106 adult patients. Data from the two studies showed that Visipaque has a 99 percent negative predictive value in the diagnosis of CAD (study 1: sensitivity (76-89 percent), specificity (84-89 percent); study 2: sensitivity (95 percent), specificity (87 percent))[1]. Visipaque’s label extension further enhances GE Healthcare’s cardiology portfolio, joining, Myoview, Adreview, and the recently announced distribution rights for Rapiscan outside the U.S. and Canada.

For more information: www3.gehealthcare.com/en/products/categories/contrast_media/visipaque

Related Content

Coronary CT angiography (CCTA or CTA) images courtesy of Canon Medical Systems.

Coronary CT angiography images courtesy of Canon Medical Systems.

News | CT Angiography (CTA) | January 18, 2021
An example of a cardiac CT scan showing a 3-D reconstriction of the heart showing a stented vessel, and reformatted images showing the stented coronary artery with restenosis from different views. This was imaged using a Canon Aquilion Prime CT system.

An example of a cardiac CT scan showing a 3-D reconstriction of the heart showing a stented vessel, and reformatted images showing the stented coronary artery with restenosis from different views. This was imaged using a Canon Aquilion Prime CT system.

Feature | CT Angiography (CTA) | September 08, 2020
September 8, 2020 — The Journal of the Am
A calcium scoring CT scan showing a segment of heavily calcified coronary artery.

A calcium scoring CT scan showing a segment of heavily calcified coronary artery

News | CT Angiography (CTA) | August 20, 2020
August 20, 2020 – The amount of calcified plaque in the heart’s arteries on...
Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG). #SCCT2020 #yesCCT

Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG).

Feature | CT Angiography (CTA) | August 14, 2020 | Dave Fornell, Editor
The latest technical advances and trends in...
During the SCCT 2020 virtual meeting, SCCT President Ron Blackstein, M.D., Brigham and Women's, presents the SCCT Gold Award to John Lesser, M.D., MSCCT, director of advanced imaging and cardiac CT, Minneapolis Heart Institute, Abbott Northwestern Hospital. 

During the SCCT 2020 virtual meeting, SCCT President Ron Blankstein, M.D., Brigham and Women's, presented the SCCT Gold Award to John Lesser, M.D., MSCCT, director of advanced imaging and cardiac CT, Minneapolis Heart Institute, Abbott Northwestern Hospital. 

News | CT Angiography (CTA) | August 14, 2020 | Dave Fornell, Editor
An example of perivascular fat attenuation index (FAI) imaging inside the coronary vascular wall to show areas of inflammation. #SCCT2020

An example of perivascular fat attenuation index (FAI) imaging inside the coronary vascular wall to show areas of inflammation. The technology was created by Oxford University and several experts in cardiac CT imaging say this might be a game changer to improving risk assessments.

Feature | CT Angiography (CTA) | July 30, 2020 | Dave Fornell, Editor
There is a promising recent development in...